Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

By Richard M. Stone, D. DeAngelo, V. Klimek, I. Galinsky, E. Estey, Stephen D. Nimer, W. Grandin, D. Lebwohl, Yanfeng Wang, P. Cohen and 5 more. Blood, 2005

714 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/cf21d583d1c075bebfeb8b173e11844b43eb8a50

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. H. Kantarjian

In Hematology

1. H. Kantarjian

Citations in the corpus

• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. (2009, background): “However, with the exception of CML, these therapies have yet to substantively improve outcomes for patients with myeloid malignancies.(17,18) This may reflect insufficient target inhibition, or, alternatively, this may indicate incomplete dependence on these activated pathways due to the presence of”